 Yuki Fujiwara
Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macrophages | 15 | 2025 | 1480 | 1.230 |
Why?
| | Macrophage Activation | 8 | 2025 | 189 | 1.230 |
Why?
| | B7-H1 Antigen | 7 | 2025 | 196 | 1.120 |
Why?
| | Receptors, G-Protein-Coupled | 3 | 2024 | 207 | 1.020 |
Why?
| | Immunity | 3 | 2021 | 139 | 0.890 |
Why?
| | Sialic Acid Binding Ig-like Lectin 1 | 3 | 2025 | 4 | 0.880 |
Why?
| | Tumor Microenvironment | 10 | 2025 | 634 | 0.660 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 2061 | 0.650 |
Why?
| | Immunologic Factors | 2 | 2018 | 231 | 0.650 |
Why?
| | Cell Line, Tumor | 16 | 2025 | 3215 | 0.640 |
Why?
| | Flavanones | 2 | 2022 | 4 | 0.630 |
Why?
| | Thalidomide | 1 | 2018 | 32 | 0.600 |
Why?
| | Neoplasms | 6 | 2025 | 2470 | 0.600 |
Why?
| | Diosgenin | 1 | 2018 | 1 | 0.590 |
Why?
| | Saponins | 1 | 2018 | 8 | 0.580 |
Why?
| | Immunomodulation | 1 | 2018 | 93 | 0.570 |
Why?
| | Atherosclerosis | 3 | 2024 | 402 | 0.560 |
Why?
| | Hyaluronan Receptors | 1 | 2018 | 96 | 0.560 |
Why?
| | Extracellular Matrix Proteins | 1 | 2018 | 144 | 0.530 |
Why?
| | Mice | 24 | 2025 | 16937 | 0.520 |
Why?
| | Cell Proliferation | 11 | 2025 | 2391 | 0.480 |
Why?
| | Breast Neoplasms | 3 | 2023 | 2142 | 0.450 |
Why?
| | Immunotherapy | 6 | 2023 | 592 | 0.430 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1928 | 0.420 |
Why?
| | Tomatine | 1 | 2012 | 1 | 0.390 |
Why?
| | Sterol O-Acyltransferase | 1 | 2012 | 5 | 0.390 |
Why?
| | Animals | 26 | 2025 | 35360 | 0.380 |
Why?
| | Apolipoproteins E | 1 | 2012 | 77 | 0.380 |
Why?
| | Macrophages, Peritoneal | 2 | 2024 | 91 | 0.370 |
Why?
| | Hyperlipidemias | 1 | 2012 | 126 | 0.360 |
Why?
| | Plaque, Atherosclerotic | 2 | 2024 | 55 | 0.360 |
Why?
| | Lymph Nodes | 3 | 2025 | 472 | 0.360 |
Why?
| | Down-Regulation | 2 | 2017 | 636 | 0.350 |
Why?
| | Plant Extracts | 1 | 2012 | 199 | 0.330 |
Why?
| | Melanoma, Experimental | 2 | 2022 | 108 | 0.330 |
Why?
| | STAT3 Transcription Factor | 4 | 2023 | 195 | 0.310 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2023 | 89 | 0.310 |
Why?
| | Aorta | 2 | 2024 | 411 | 0.310 |
Why?
| | Mice, Inbred C57BL | 11 | 2024 | 5440 | 0.310 |
Why?
| | Anti-Inflammatory Agents | 2 | 2024 | 480 | 0.300 |
Why?
| | Mice, Knockout | 6 | 2025 | 2871 | 0.290 |
Why?
| | Interferon-alpha | 2 | 2025 | 194 | 0.250 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2025 | 211 | 0.240 |
Why?
| | Photochemotherapy | 1 | 2024 | 32 | 0.220 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2024 | 19 | 0.220 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2022 | 1356 | 0.220 |
Why?
| | Aortic Diseases | 1 | 2024 | 115 | 0.210 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 191 | 0.210 |
Why?
| | Neovascularization, Pathologic | 1 | 2025 | 297 | 0.210 |
Why?
| | Interleukin-6 | 3 | 2023 | 720 | 0.200 |
Why?
| | Cell Communication | 3 | 2023 | 301 | 0.200 |
Why?
| | Mice, Inbred BALB C | 2 | 2024 | 1245 | 0.200 |
Why?
| | Membrane Glycoproteins | 1 | 2025 | 474 | 0.190 |
Why?
| | Colonic Neoplasms | 2 | 2024 | 243 | 0.190 |
Why?
| | Interleukin-10 | 2 | 2021 | 304 | 0.190 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2024 | 232 | 0.190 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 16 | 0.190 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 26 | 0.190 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 34 | 0.190 |
Why?
| | Sulfur Compounds | 1 | 2021 | 7 | 0.190 |
Why?
| | Heparin-binding EGF-like Growth Factor | 1 | 2021 | 15 | 0.190 |
Why?
| | Orosomucoid | 1 | 2021 | 6 | 0.190 |
Why?
| | CD47 Antigen | 1 | 2021 | 28 | 0.190 |
Why?
| | Osteopontin | 1 | 2021 | 31 | 0.190 |
Why?
| | Immunotherapy, Adoptive | 1 | 2025 | 295 | 0.190 |
Why?
| | Glioblastoma | 1 | 2025 | 326 | 0.180 |
Why?
| | Interleukin-12 | 2 | 2022 | 118 | 0.180 |
Why?
| | Neuropeptides | 1 | 2021 | 71 | 0.180 |
Why?
| | Mouth Neoplasms | 1 | 2022 | 86 | 0.180 |
Why?
| | Phagocytes | 1 | 2021 | 97 | 0.180 |
Why?
| | Signal Transduction | 7 | 2024 | 4925 | 0.180 |
Why?
| | Burns, Electric | 1 | 2020 | 26 | 0.170 |
Why?
| | Immune Tolerance | 1 | 2023 | 355 | 0.170 |
Why?
| | Phenotype | 3 | 2025 | 3076 | 0.170 |
Why?
| | Humans | 22 | 2025 | 129622 | 0.160 |
Why?
| | Ligands | 1 | 2021 | 622 | 0.160 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 171 | 0.160 |
Why?
| | HEK293 Cells | 1 | 2021 | 697 | 0.150 |
Why?
| | Kupffer Cells | 1 | 2018 | 49 | 0.150 |
Why?
| | Hepatitis | 1 | 2018 | 47 | 0.150 |
Why?
| | Membrane Proteins | 2 | 2021 | 1119 | 0.150 |
Why?
| | Aortitis | 1 | 2018 | 10 | 0.150 |
Why?
| | Disease Progression | 6 | 2024 | 2635 | 0.150 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2018 | 220 | 0.150 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 60 | 0.140 |
Why?
| | Interferon Type I | 1 | 2018 | 139 | 0.140 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2023 | 169 | 0.140 |
Why?
| | Neoplasm Transplantation | 3 | 2024 | 257 | 0.140 |
Why?
| | Sulfoxides | 1 | 2016 | 3 | 0.130 |
Why?
| | Disease Models, Animal | 5 | 2024 | 4063 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2022 | 626 | 0.130 |
Why?
| | T-Lymphocyte Subsets | 1 | 2018 | 412 | 0.130 |
Why?
| | Lymphoma | 1 | 2017 | 196 | 0.130 |
Why?
| | Brain Neoplasms | 1 | 2025 | 1171 | 0.130 |
Why?
| | Receptors, Cell Surface | 1 | 2018 | 380 | 0.130 |
Why?
| | Sarcoma | 1 | 2018 | 176 | 0.120 |
Why?
| | Interleukin-1beta | 1 | 2018 | 372 | 0.120 |
Why?
| | Thiophenes | 1 | 2016 | 118 | 0.120 |
Why?
| | Liver Neoplasms | 1 | 2020 | 640 | 0.120 |
Why?
| | Antigens, CD | 1 | 2018 | 489 | 0.120 |
Why?
| | Toll-Like Receptor 4 | 2 | 2021 | 263 | 0.120 |
Why?
| | Liver | 2 | 2020 | 1839 | 0.120 |
Why?
| | Melanoma | 1 | 2022 | 730 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2022 | 825 | 0.110 |
Why?
| | Adenocarcinoma | 1 | 2020 | 898 | 0.110 |
Why?
| | Pancreatic Neoplasms | 1 | 2020 | 882 | 0.100 |
Why?
| | Cholesterol Esters | 1 | 2012 | 7 | 0.100 |
Why?
| | Foam Cells | 1 | 2012 | 15 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2023 | 2344 | 0.100 |
Why?
| | Mice, Knockout, ApoE | 2 | 2024 | 11 | 0.100 |
Why?
| | Female | 9 | 2025 | 68770 | 0.090 |
Why?
| | Cricetinae | 1 | 2012 | 277 | 0.090 |
Why?
| | Scavenger Receptors, Class A | 1 | 2011 | 11 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1706 | 0.090 |
Why?
| | Cell Line | 2 | 2018 | 2781 | 0.090 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 490 | 0.090 |
Why?
| | Cells, Cultured | 3 | 2024 | 4083 | 0.080 |
Why?
| | Coculture Techniques | 2 | 2021 | 226 | 0.080 |
Why?
| | Cell Movement | 2 | 2022 | 945 | 0.070 |
Why?
| | Mice, Transgenic | 2 | 2025 | 2119 | 0.060 |
Why?
| | Bevacizumab | 1 | 2025 | 129 | 0.060 |
Why?
| | Survival Rate | 2 | 2020 | 1877 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2025 | 132 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2024 | 274 | 0.050 |
Why?
| | Enzyme Activation | 1 | 2024 | 811 | 0.050 |
Why?
| | Administration, Oral | 1 | 2024 | 786 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2024 | 231 | 0.050 |
Why?
| | Male | 7 | 2025 | 63674 | 0.050 |
Why?
| | Reactive Oxygen Species | 1 | 2024 | 596 | 0.050 |
Why?
| | Antibodies | 1 | 2023 | 398 | 0.050 |
Why?
| | MCF-7 Cells | 1 | 2021 | 116 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 2021 | 273 | 0.040 |
Why?
| | Tumor Burden | 1 | 2022 | 286 | 0.040 |
Why?
| | Arginase | 1 | 2020 | 32 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2024 | 432 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2021 | 143 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 2021 | 216 | 0.040 |
Why?
| | Hepatocytes | 1 | 2021 | 216 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2021 | 177 | 0.040 |
Why?
| | Phagocytosis | 1 | 2021 | 362 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2021 | 213 | 0.040 |
Why?
| | Mannose | 1 | 2018 | 25 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 381 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 159 | 0.040 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2020 | 170 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 274 | 0.040 |
Why?
| | RAW 264.7 Cells | 1 | 2018 | 49 | 0.040 |
Why?
| | Mice, Inbred ICR | 1 | 2018 | 110 | 0.040 |
Why?
| | Survival Analysis | 1 | 2022 | 1274 | 0.040 |
Why?
| | Monocytes | 1 | 2021 | 551 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2018 | 73 | 0.040 |
Why?
| | Serum Albumin | 1 | 2018 | 149 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 530 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2021 | 770 | 0.040 |
Why?
| | Apoptosis | 2 | 2017 | 2503 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 383 | 0.040 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2018 | 252 | 0.040 |
Why?
| | Tyrphostins | 1 | 2017 | 17 | 0.040 |
Why?
| | Middle Aged | 3 | 2025 | 31150 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1206 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2018 | 285 | 0.030 |
Why?
| | Necrosis | 1 | 2018 | 232 | 0.030 |
Why?
| | Chemokine CCL4 | 1 | 2017 | 23 | 0.030 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 38 | 0.030 |
Why?
| | Caspase 3 | 1 | 2017 | 245 | 0.030 |
Why?
| | Cytokines | 2 | 2016 | 2017 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2020 | 370 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 749 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 857 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2121 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 434 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2018 | 1304 | 0.030 |
Why?
| | Fibrosis | 1 | 2018 | 520 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2018 | 505 | 0.030 |
Why?
| | Pyridines | 1 | 2017 | 478 | 0.030 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2011 | 17 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2011 | 179 | 0.020 |
Why?
| | Shock, Septic | 1 | 2011 | 209 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 2704 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2011 | 582 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 875 | 0.020 |
Why?
| | NF-kappa B | 1 | 2011 | 653 | 0.020 |
Why?
| | Inflammation | 1 | 2011 | 2736 | 0.010 |
Why?
| | Aged | 1 | 2018 | 22099 | 0.010 |
Why?
|
|
Fujiwara's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|